ATYR
aTyr Pharma, Inc.
Healthcare — Biotechnology
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Price History
Fundamentals
| Market Cap | $47.62M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.77 |
| EPS (TTM) | $-0.74 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -105.63% |
| Debt/Equity | 20.26 |
| Recommendation | None |
| Analyst Target | $2.86 |
| Analysts | 7 |
| Next Earnings | Aug 7, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 45.3 |
| Beta | 0.52 |
| SMA 20 | $0.52 |
| SMA 40 | $0.51 |
| 52-Week High | $6.50 |
| 52-Week Low | $0.40 |
| 50-Day Avg | $0.51 |
| 200-Day Avg | $0.74 |
| Avg Volume | $2.73M |
| Volume | 394.0K |
Performance Analysis
NEUTRALATYR presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Aug 01, 2026 04:13 UTC
Back to Screener Export Report